Targeting both

Inflammation and

Mitochondrial Dysfunction

for the treatment of Diseases

with high unmet need

Unlocking the Full Therapeutic Value of Natural Cell Protection Pathways

OMEICOS Therapeutics is focused on developing therapies that have the potential for a significant impact on cardiovascular, inflammatory and mitochondrial diseases with high unmet need. Our pipeline is based on our proprietary approach to target one of nature’s most important cell-protective pathways and industry-leading knowledge of omega-3 fatty acid metabolism and biology.

OMEICOS lead compound, OMT-28, has recently completed a double-blinded, placebo-controlled, multi-center Phase 2 clinical trial in patients suffering from atrial fibrillation – less than 7 years after founding the company in Berlin. The trial was inconclusive on the impact on atrial fibrillation but OMT-28 was safe and well tolerated. In addition, the study demonstrated a positive effect on a number of inflammatory biomarkers that are of importance in cardiovascular disease, e.g. for the reduction of disease progression and adverse events in patients with Coronary Artery Disease. The company is planning a robust clinical proof-of-concept study to confirm this effect and its potential in treating cardiovascular disease.

OMEICOS has also demonstrated the potential of OMT-28 in both inflammation and mitochondrial dysfunction and has plans for a proof-of-concept clinical study in cardiomyopathy in patients with mitochondriopathies. In addition, OMT-28 has shown potential for the application to other disease areas such as ophthalmology.

Latest Press Release

September 3, 2019
OMEICOS Therapeutics Appoints Dr Simon Russell as Chief Business Officer
Read more

Upcoming Events

October 25 - 28, 2021
BIO Europe Digital 2021
Read more

Pipeline